A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
A phase 1/2 trial of ANS02 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.
Overview
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07538804 by Avistone Biotechnology Co., Ltd., with 294 participants planned, started 2026-07-10 and due to reach its primary completion in 2029-06-30. Interventions recorded: ANS02.
Similar pages
not linked directly; found by shared links- TrialA Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Shares Avistone Biotechnology, Non-small-cell lung cancer and the tag pipeline.
- TrialAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Shares Avistone Biotechnology, Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialFirst-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Shares Non-small-cell lung cancer and the tag pipeline.